Mucosal delivery of a double-stapled RSV peptide prevents nasopulmonary infection

Journal of Clinical Investigation

Volumn 124, Issue 5, 2014, Pages 2113-2124

  Bird, Gregory H ^a,b   Boyapalle, Sandhya ^c,d   Wong, Terianne ^c,d,e   Opoku Nsiah, Kwadwo ^a   Bedi, Raminder ^d   Crannell, W Christian ^a   Perry, Alisa F ^a   Nguyen, Huy ^c   Sampayo, Viviana ^c   Devareddy, Ankita ^c   Mohapatra, Subhra ^c,d,e   Mohapatra, Shyam S ^c,d   Walensky, Loren D ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF SOUTH FLORIDA   (United States)

^e UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHITOSAN; HYBRID PROTEIN; HYDROCARBON; NANOPARTICLE; RECOMBINANT PROTEIN; RESPIRATORY SYNCITIAL VIRUS PEPTIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL ISOLATION; CONTROLLED STUDY; DISEASE COURSE; FEMALE; LUNG INFECTION; MOUSE; MURINAE; NASOPULMONARY INFECTION; NONHUMAN; NOSE INFECTION; PRIORITY JOURNAL; PROTEIN STRUCTURE; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY SYNCYTIAL VIRUS INFECTION; SINGLE DRUG DOSE; TREATMENT DURATION; VIRUS ISOLATION;

ANIMALS; CELL LINE; CHITOSAN; DISEASE MODELS, ANIMAL; FEMALE; MICE; MICE, INBRED BALB C; NANOPARTICLES; NOSE DISEASES; PEPTIDES; PNEUMONIA, VIRAL; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUSES; VIRAL FUSION PROTEINS;

EID: 84899715084     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI71856     Document Type: Article

References (46)

1. Initiative for Vaccine Research. Acute Respiratory Infection. Geneva, Switzerland: World Health Organization; 2009.
2. Karron RA. Respiratory syncytial virus and parainfluenza virus vaccines. In: Plotkin SA, Orenstein WA, Offit PA, eds. Vaccines. 5th ed. New York, New York, USA: Saunders Elsevier; 2008:1283-1293.
3. Thompson WW, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA. 2003;289(2):179-186.
4. Falsey AR, Walsh EE. Respiratory syncytial virus infection in adults. Clin Microbiol Rev. 2000;13(3):371-384.
5. Han LL, Alexander JP, Anderson LJ. Respiratory syncytial virus pneumonia among the elderly: an assessment of disease burden. J Infect Dis. 1999; 179(1):25-30.
6. Mullooly JP, et al. Influenza- and RSV-associated hospitalizations among adults. Vaccine. 2007; 25(5):846-855.
7. Falsey AR, Walsh EE. Respiratory syncytial virus infection in elderly adults. Drugs Aging. 2005;22(7):577-587.
8. Centers for Disease Control and Prevention (CDC). Respiratory syncytial virus activity - United States, 1999-2000 season. MMWR Morb Mortal Wkly Rep. 2000;49(48):1091-1093.
9. Silva A, Erickson JE, Eissenstat M, Afonina E, Gulnik, S, inventors; Sequoia Pharmaceuticals, assignee. Long acting biologically active conjugates. US patent 10/550,715. March 24, 2003.
10. Hall CB, et al. Respiratory syncytial viral infection in children with compromised immune function. N Engl J Med. 1986;315(2):77-81.
11. Lambert DM, et al. Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. Proc Natl Acad Sci U S A. 1996;93(5):2186-2191.
12. Pastey MK, Gower TL, Spearman PW, Crowe JE, Crowe JE Jr, Graham BS. A RhoA-derived peptide inhibits syncytium formation induced by respiratory syncytial virus and parainfluenza virus type 3 Nat Med. 2000;6(1):35-40.
13. Shepherd NE, Hoang HN, Desai VS, Letouze E, Young PR, Fairlie DP. Modular alpha-helical mimetics with antiviral activity against respiratory syncitial virus. J Am Chem Soc. 2006;128(40):13284-13289.
14. Cianci C, Meanwell N, Krystal M. Antiviral activity and molecular mechanism of an orally active respiratory syncytial virus fusion inhibitor. J Antimicrob Chemother. 2005;55(3):289-292.
15. Douglas JL, et al. Inhibition of respiratory syncytial virus fusion by the small molecule VP-14637 via specific interactions with F protein. J Virol. 2003; 77(9):5054-5064.
16. Olszewska W, et al. Antiviral and lung protective activity of a novel respiratory syncytial virus fusion inhibitor in a mouse model. Eur Respir J. 2011;38(2):401-408.
17. Razinkov V, Gazumyan A, Nikitenko A, Ellestad G, Krishnamurthy G. RFI-641 inhibits entry of respiratory syncytial virus via interactions with fusion protein. Chem Biol. 2001;8(7):645-659.
18. Roymans D, et al. Binding of a potent smallmolecule inhibitor of six-helix bundle formation requires interactions with both heptad-repeats of the RSV fusion protein. Proc Natl Acad Sci U S A. 2010;107(1):308-313.
19. Kumar M, et al. Intranasal gene transfer by chitosan- DNA nanospheres protects BALB/c mice against acute respiratory syncytial virus infection. Hum Gene Ther. 2002;13(12):1415-1425.
20. Kumar M, Behera AK, Matsuse H, Lockey RF, Mohapatra SS. Intranasal IFN- gene transfer protects BALB/c mice against respiratory syncytial virus infection. Vaccine. 1999;18(5-6):558-567.
21. Zhang W, et al. Inhibition of respiratory syncytial virus infection with intranasal siRNA nanoparticles targeting the viral NS1 gene. Nat Med. 2005; 11(1):56-62.
22. Garg R, Latimer L, Simko E, Gerdts V, Potter A, van den Hurk Sv. Induction of mucosal immunity and protection by intranasal immunisation with a novel respiratory syncytial virus vaccine formulation. J Gen Virol. 2014;95(pt 2):301-306.
23. McLellan JS, et al. Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science. 2013;340(6136):1113-1117.
24. Stab V, et al. Protective efficacy and immunogenicity of a combinatory DNA vaccine against Influenza A Virus and the Respiratory Syncytial Virus. PLoS One. 2013;8(8):e72217.
25. McLellan JS, et al. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science. 2013;342(6158):592-598.
26. Zhao X, Singh M, Malashkevich VN, Kim PS. Structural characterization of the human respiratory syncytial virus fusion protein core. Proc Natl Acad Sci U S A. 2000;97(26):14172-14177.
27. Melikyan GB. Common principles and intermediates of viral protein-mediated fusion: the HIV-1 paradigm. Retrovirol. 2008;5:111.
28. Kilby JM, et al. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41- mediated virus entry. Nat Med. 1998;4(11):1302-1307.
29. Lawless-Delmedico MK, et al. Heptad-repeat regions of respiratory syncytial virus F-1 protein form a sixmembered coiled-coil complex. Biochemistry. 2000; 39(38):11684-11695.
30. Schafmeister CE, Po J, Verdine GL. An all-hydrocarbon cross-linking system for enhancing the helicity and metabolic stability of peptides. J Am Chem Soc. 2000;122:5891-5892.
31. Walensky LD, et al. Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix. Science. 2004;305(5689):1466-1470.
32. Bird GH, et al. Hydrocarbon double-stapling remedies the proteolytic instability of a lengthy peptide therapeutic. Proc Natl Acad Sci U S A. 2010; 107(32):14093-14098.
33. Root MJ, Kay MS, Kim PS. Protein design of an HIV-1 entry inhibitor. Science. 2001;291(5505):884-888.
34. Moore ML, et al. A chimeric A2 strain of respiratory syncytial virus (RSV) with the fusion protein of RSV strain line 19 exhibits enhanced viral load, mucus, and airway dysfunction. J Virol. 2009; 83(9):4185-4194.
35. Sakai T, et al. Dual wavelength imaging allows analysis of membrane fusion of influenza virus inside cells. J Virol. 2006;80(4):2013-2018.
36. Bolger G, et al. Primary infection of mice with high titer inoculum respiratory syncytial virus: characterization and response to antiviral therapy. Can J Physiol Pharmacol. 2005;83(2):198-213.
37. Sudo K, Watanabe W, Mori S, Konno K, Shigeta S, Yokota T. Mouse model of respiratory syncytial virus infection to evaluate antiviral activity in vivo. Antivir Chem Chemother. 1999;10(3):135-139.
38. Takeshita T, et al. Effect of brazilian propolis on exacerbation of respiratory syncytial virus infection in mice exposed to tetrabromobisphenol a, a brominated flame retardant. Evid Based Complement Alternat Med. 2013;2013:698206.
39. Bird GH, Crannell CW, Walensky LD. Chemical synthesis of hydrocarbon-stapled peptides for protein interaction research and therapeutic Targeting. Curr Protoc Chem Biol. 2011;3(3):99-117.
40. Bird GH, Bernal F, Pitter K, Walensky LD. Synthesis and biophysical characterization of stabilized alpha-helices of BCL-2 domains. Methods Enzymol. 2008;446:369-386.
41. Hallak LK, Collins PL, Knudson W, Peeples ME. Iduronic acid-containing glycosaminoglycans on target cells are required for efficient respiratory syncytial virus infection. Virology. 2000;271(2):264-275.
42. Bitko V, Musiyenko A, Shulyayeva O, Barik S. Inhibition of respiratory viruses by nasally administered siRNA. Nat Med. 2005;11(1):50-55.
43. Perkins SM, et al. Comparison of a real-time reverse transcriptase PCR assay and a culture technique for quantitative assessment of viral load in children naturally infected with respiratory syncytial virus. J Clin Microbiol. 2005;43(5):2356-2362.
44. San-Juan-Vergara H, et al. Cholesterol-rich microdomains as docking platforms for respiratory syncytial virus in normal human bronchial epithelial cells. J Virol. 2012;86(3):1832-1843.
45. San-Juan-Vergara H, Peeples ME, Lockey RF, Mohapatra SS. Protein kinase C-alpha activity is required for respiratory syncytial virus fusion to human bronchial epithelial cells. J Virol. 2004;78(24):13717-13726.
46. Boyapalle S, Wong T, Garay J, Teng M, San Juan-Vergara H, Mohapatra S. Respiratory syncytial virus NS1 protein colocalizes with mitochondrial antiviral signaling protein MAVS following infection. PLoS One. 2012;7(2):e29386.